Overview

PRETELL: PREvention of TELomere-related Complications After Lung Transplant

Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of Danzol in lung transplant recipients with short telomeres. Subjects with short telomeres recipient of lung transplant, will be randomized in the first month post-transplant to either placebo or Danazol (200mg bid) in a 2:1 ratio.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Brigham and Women's Hospital
Treatments:
Danazol